{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Moreira-Barbosa C"],"funding":["Núcleo Regional da Madeira da Liga Portuguesa Contra o Cancro &amp; Diário de Notícias","Research Center - Portuguese Oncology Institute of Porto"],"pagination":["132"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6206889"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(1)"],"pubmed_abstract":["<h4>Background</h4>Prostate cancer (PCa) is one of the most common cancers among men worldwide. Current screening methods for PCa display limited sensitivity and specificity, not stratifying for disease aggressiveness. Hence, development and validation of new molecular markers is needed. Aberrant gene promoter methylation is common in PCa and has shown promise as clinical biomarker. Herein, we assessed and compared the diagnostic and prognostic performance of two-gene panel promoter methylation in the same sample sets.<h4>Methods</h4>Promoter methylation of panel #1 (singleplex-miR-34b/c and miR-193b) and panel #2 (multiplex-APC, GSTP1, and RARβ2) was evaluated using MethyLight methodology in two different cohorts [prostate biopsy (#1) and urine sediment (#2)]. Biomarkers' diagnostic (vali"],"journal":["Clinical epigenetics"],"pubmed_title":["Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients."],"pmcid":["PMC6206889"],"funding_grant_id":["2016","CI-IPOP-BI-GEBC2018/UID/DTP/00776/POCI-01-0145-FEDER-006868","Grant PI 74-CI-IPOP-19-2015"],"pubmed_authors":["Henrique R","Antunes L","Costa-Pinheiro P","Moreira-Barbosa C","Barros-Silva D","Freitas R","Jeronimo C","Constancio V","Torres-Ferreira J","Oliveira J"],"additional_accession":[]},"is_claimable":false,"name":"Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients.","description":"<h4>Background</h4>Prostate cancer (PCa) is one of the most common cancers among men worldwide. Current screening methods for PCa display limited sensitivity and specificity, not stratifying for disease aggressiveness. Hence, development and validation of new molecular markers is needed. Aberrant gene promoter methylation is common in PCa and has shown promise as clinical biomarker. Herein, we assessed and compared the diagnostic and prognostic performance of two-gene panel promoter methylation in the same sample sets.<h4>Methods</h4>Promoter methylation of panel #1 (singleplex-miR-34b/c and miR-193b) and panel #2 (multiplex-APC, GSTP1, and RARβ2) was evaluated using MethyLight methodology in two different cohorts [prostate biopsy (#1) and urine sediment (#2)]. Biomarkers' diagnostic (vali","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Oct","modification":"2026-05-05T23:06:11.018Z","creation":"2019-03-27T00:05:39Z"},"accession":"S-EPMC6206889","cross_references":{"pubmed":["30373654"],"doi":["10.1186/s13148-018-0564-2"]}}